Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz - Gilde Healthcare

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

November 20, 2023
Utrecht (the Netherlands) and Spaichingen (Germany)

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago.

Koscher & Würtz (K&W) will join as a group company next to Chr. Diener, together employing about 300 highly qualified staff members. By joining forces, K&W and Chr. Diener will be able to offer their clients an even broader portfolio of products, while benefitting from sharing of expertise and best practices. The joint vision is to create a leading contract manufacturer in precision medical instruments.

Headquartered in Spaichingen (Germany), K&W develops and manufactures reusable- and disposable surgical instruments for world-class Original Equipment Manufacturers. Founded in 1983, K&W grew out to a leading player in its market niche. Its continued focus on quality and customers‘ satisfaction has resulted in long-term customer relationships and allowed the company to grow with its clients.

Chr. Diener was acquired by Gilde Healthcare in July 2022. Founded in 1900, The company builds on a long heritage of surgical instrument making. Today, the company has a market leading reputation for designing and manufacturing customer-specific reusable instruments for leading international clients. With Gilde’s support, Chr. Diener expanded its production capacity, readying the company for further organic growth.

Stefan Koscher and Johann Würtz Co-CEOs of K&W stated: “We are very proud of the development of K&W which we have achieved with our team since founding the company 40 years ago. We are pleased to have a new partner at our side and look forward to the next steps we will jointly pursue. We are convinced that being part of a large instrument manufacturing group will bring great value to its member companies and help build a global leader.”

Rafael Natanek, General Partner at Gilde Healthcare Private Equity, commented: ‘’We are impressed by K&W’s success over the last years and the achievements of the entire management team. We are excited to partner with Stefan, Johann and their team to support the future growth path. K&W adds an important additional segment in form of disposable instruments to the group. There is also a great strategic fit between K&W and Chr. Diener.”

About Koscher & Würtz
Koscher & Würtz is a reliable and highly productive family-run enterprise specialized in medical engineering. By having specialized in the production of surgical hand-held precision instruments, they have been successful in ensuring high customer satisfaction. More than 200 excellently-qualified and highly-motivated staff members are contributors to the success. By providing modern workplaces, high-precision tools as well as state-of-the-art machinery, K&W enables its staff to profit from an ideal work environment. www.koscher-wuertz.de

About Chr. Diener
The name Chr. Diener has been synonymous with excellence in the manufacture of surgical instruments since 1900. When it comes to orthopaedic- and spinal surgery, they have established a sound reputation as a producer of highly complex instruments complying to the most stringent quality standards. Headquartered in Tuttlingen (Germany), with 90 employees, the company caters to clients globally. www.diener-gmbh.de

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com

Media contact:
Rafael Natanek (general partner Gilde Healthcare)
email: natanek@gildehealthcare.com

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
November 25, 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024